After high-altitude exposure , significantly fewer participants in the budesonide ( 23.81 % ) and dexamethasone ( 30.77 % ) groups developed acute mountain sickness compared with participants receiving placebo ( 60.46 % ) ( P = .0006 and P = .0071 , respectively ) .